US Pharma MarketingAnti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027
NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies…
The Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate.
NewLimit said Tuesday it has raised ...
Source: Endpoints News